Objective:

To address the challenges facing the generic and biosimilars market and propose policy changes to ensure long-term access to cost-saving medicines for patients.

Approach:

• Policy Proposals: The Association for Accessible Medicines (AAM) announced a series of policy proposals aimed at ensuring patient access to lower-cost medicines.
• Supply Chain Resilience: Despite short-term strains during the pandemic, the global supply chain for generics proved resilient, with supply ultimately matching demand.
• Support for Domestic Manufacturing: Policymakers should expand the Strategic National Stockpile to include essential medicines manufactured in the US and support economic conditions for domestic manufacturing.
• Addressing Competitive Imbalances: The market faces competitive imbalances due to a consolidated drug purchasing system and government policies that negatively impact generic manufacturers.
• Encouraging Adoption of Generics and Biosimilars: Policies should be updated to encourage the adoption of lower-cost generics and biosimilars, particularly in Medicare Part D and Part B.

Key Findings:

• Generic drug manufacturers ensured a stable supply of medicines during the COVID-19 pandemic.
• The Medicaid Generic Penalty imposes financial risks on manufacturers, contributing to potential shortages.
• Government and payer policies currently hinder patient adoption of lower-cost generics and biosimilars.

Interpretation:

Limitations:

• The article does not provide specific data on the impact of proposed policy changes.
• It does not address potential resistance from stakeholders benefiting from current high-cost brand drug policies.

Conclusion:

Addressing these challenges is essential for ensuring a secure supply of generic and biosimilar medicines and promoting patient savings.

Sources:

• Association for Accessible Medicines